CYP3A4 and primary adrenal insufficiency: The European Medicines Agency (EMA) stated that contraindications for the use of finerenone are hypersensitivity to the drug, Addison’s disease and the simultaneous use of strong CYP3A4-inhibitors because finerenone is mainly cleared by CYP3A4.